Skip to content

This text should not show on a preview page

The information on this site is for healthcare professionals only.
Are you a healthcare professional?

No
This site is not currently optimised for Internet Explorer.
For best viewing, please use Chrome, Firefox, Edge, or Safari.
  • Let's talk  Knowledge
  • Let's talk  Events
  • Let's talk  Innovation
  • Let's talk  Videos
  • Let's talk  Key opinions
  • Let's talk  Teva
  • Let's talk  Sign up
  • Let's talk  Knowledge
  • Let's talk  Events
  • Let's talk  Innovation
  • Let's talk  Videos
  • Let's talk  Key opinions
  • Let's talk  Teva
  • Let's talk  Sign up
  • Home
  • Coronavirus and digital health: a catalyst for change?

Search results for Electronic health records

Coronavirus and digital health: a catalyst for change?

Coronavirus and digital health: a catalyst for change?

Innovation
Utilising blockchain technology in healthcare

Utilising blockchain technology in healthcare

  • blockchain
  • EHRs
  • Electronic health records
  • interoperability
Innovation
EHRs: The good, the bad and the inefficient

EHRs: The good, the bad and the inefficient

Innovation
New perspectives: COPD and autoimmunity

New perspectives: COPD and autoimmunity

  • autoimmune disease
  • autoimmunity
  • Big data
  • big data analytics
  • COPD
  • inflammation
Knowledge
What’s the big deal with big data?

What’s the big deal with big data?

  • Data
  • Technology
Innovation 6 min read
Abstract particle graph background.

Small data vs. big data: personalisation or generalisation?

  • Data
  • Technology
Innovation 6 min read
  • Let's talk  Contact
  • Let's talk  Legal notice
  • Let's talk  Privacy policy
  • Let's talk  Report Adverse Events
© 2020 Teva Pharmaceuticals Europe BV. All rights reserved. Reporting of suspected adverse events is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. To ensure correct adverse event reporting, healthcare professionals are encouraged to use the appropriate website for their National Authority.
Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands.
Approval code: HQ/RESP/19/0001a Date of preparation: May 2019

This website uses cookies to ensure you get the best experience on our website. Learn more in our cookie policy

Thank you for your visit.
You are now leaving the website.
Do you wish to continue?